American Century Companies Inc. Has $12.77 Million Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

American Century Companies Inc. raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 234.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 526,569 shares of the biopharmaceutical company’s stock after buying an additional 369,160 shares during the quarter. American Century Companies Inc. owned 0.43% of Catalyst Pharmaceuticals worth $12,769,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Castlekeep Investment Advisors LLC acquired a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at $37,494,000. Bank of America Corp DE lifted its stake in shares of Catalyst Pharmaceuticals by 139.5% during the fourth quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock valued at $32,741,000 after acquiring an additional 913,843 shares during the period. Nuveen LLC bought a new stake in Catalyst Pharmaceuticals in the first quarter valued at about $17,185,000. Allianz Asset Management GmbH increased its holdings in Catalyst Pharmaceuticals by 397.8% in the first quarter. Allianz Asset Management GmbH now owns 694,125 shares of the biopharmaceutical company’s stock valued at $16,833,000 after purchasing an additional 554,674 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Catalyst Pharmaceuticals by 41.7% in the first quarter. Invesco Ltd. now owns 1,199,627 shares of the biopharmaceutical company’s stock valued at $29,091,000 after purchasing an additional 352,776 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 5th. Wall Street Zen cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $33.20.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 1,600 shares of the firm’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the sale, the insider owned 41,081 shares of the company’s stock, valued at $1,085,360.02. This trade represents a 3.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $20.62 on Tuesday. The stock’s fifty day moving average price is $21.23 and its two-hundred day moving average price is $22.58. The firm has a market cap of $2.52 billion, a PE ratio of 12.50, a price-to-earnings-growth ratio of 0.86 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a one year low of $19.00 and a one year high of $26.58.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.